Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
  • entries
    84
  • comments
    0
  • views
    134

About this blog

Drug repurposing enables drug developers to optimize on past efforts and expenditure, thereby, offering a viable life cycle management strategy for marketed products and opportunities to re-evaluate failed / shelved drug development programs

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Drug Repurposing Service Providers Market, 2020-2030.

 

The report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing / repositioning / reprofiling of drug candidates. It features an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of companies offering drug repurposing services. 

§  Elaborate profiles of key players that specialize in offering services for the development of repurposed drugs.

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  An analysis of the initiatives of big biopharma players engaged in this domain.

§  A detailed analysis of more than 1,700 terminated / withdrawn / suspended clinical studies of the drug candidates.

§  A detailed analysis on the cost saving potential of drug repurposing approaches, as compared to the traditional de novo drug development methods.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  • Type of Repurposing Approaches

§  Disease-centric approach

§  Target-centric approach

§  Drug-centric approach

  • Therapeutic Area

§  Same Therapeutic Area

§  Different Therapeutic Area

  • Type of Drug Molecule

§  Biologics 

§  Small Molecule

  • Key Geographical Region 

§  North America

§  Europe

§  Asia-Pacific

 

Key companies covered in the report

§  Auxillis Pharma

§  ChemBio Discovery Solutions

§  Excelra

§  GVK Bio

§  Iris Pharma

§  Lantern Pharma

§  PanXome

§  Pharmacelera

§  Physiogenex

§  Smart Pharma

§  Socium

§  SOM Biotech

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Other Recent Offerings

1.     Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030

2.     China Biopharmaceutical Contract Manufacturing Market, 2020-2030

3.     Antibody Contract Manufacturing Market, 2020 - 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

Entries in this blog

The ‘Blood-Brain Barrier (BBB) Market, 2020-2030

Key Inclusions §  An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment

Narender

Narender in Roots Analysis

More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated

The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.   To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this https://www.rootsanalysis.com/reports

Narender

Narender in Roots Analysis

The BBB penetrating drugs market is projected to grow at an annualized rate of ~154%, till 2030

Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this https://www.rootsanalysis.com/reports/310/request-sample.html   Key Market Insights §  More tha

Narender

Narender in Roots Analysis

The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million in 2030

Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries   Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

Narender

Narender in Roots Analysis

The “Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030

Key Inclusions §  A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment.  §  A comprehensive list of novel technology pl

Narender

Narender in Roots Analysis

With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.   To order this 370+ page report, which features 90+ figures and 110+ tables, please v

Narender

Narender in Roots Analysis

The bispecific antibody therapeutics market is projected to grow at an annualized rate of ~16%

Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html   Key Market Insights          §  With two approved drugs and close to 300 clinical / preclinical prod

Narender

Narender in Roots Analysis

The bispecific antibody therapeutics market is estimated to be worth USD 6.9 billion in 2030

Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community   Roots Analysis is pleased to announce the publication of its recent study, titled, “Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030.”   The report features an extensive study of the current market landscape, offeri

Narender

Narender in Roots Analysis

The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030

Key Inclusions §  A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids an

Narender

Narender in Roots Analysis

Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions a

Narender

Narender in Roots Analysis

The biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030

Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link   Key Market Insights §  Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy pro

Narender

Narender in Roots Analysis

The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages   Roots Analysis is pleased to announce the publication of its recent study, titled,  “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”    The report features an extensive study on the contract service providers within the biopharmaceutical i

Narender

Narender in Roots Analysis

The ‘Biologics Fill / Finish Service Providers, 2019-2030

Key Inclusions §  A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease

Narender

Narender in Roots Analysis

Over 115 companies located in various regions across the globe claim to provide contract fill

Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.   To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this link   The USD

Narender

Narender in Roots Analysis

The contract fill / finish services market for biologics market is projected to grow at an annualized rate of ~10%

Roots Analysis has done a detailed study on Biologics Fill / Finish Services Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 480+ page report, which features 237 figures and 267 tables, please visit this link   Key Market Insights §  Over 115 companies located in various regions across the globe claim to provide contract fill / finish services for various types of biopharmaceutica

Narender

Narender in Roots Analysis

The contract fill / finish services market for biologics is anticipated to be worth USD 4.2 billion by 2030

A steadily growing demand for biologic fill / finish services has generated a range of new opportunities for contract service providers; stakeholders have invested heavily to ensure product integrity and safety   Roots Analysis is pleased to announce the publication of its recent study, titled, “Biologics Fill / Finish Services Market, 2019-2030.”   The report features an extensive study on the contract service providers offering drug product manufacturing services within th

Narender

Narender in Roots Analysis

The ‘AR / VR based Healthcare Digital Marketing Service Providers, 2020-2030

Key Inclusions: §  A review of the current market landscape of companies offering AR / VR based digital marketing services, featuring type of technology (AR, VR and MR), AR / VR specific services (video / content generation, website development, mobile application development and game development), additional digital marketing services (consulting, content marketing, customer relationship management, data analytics, marketing automation, product branding, quality assurance, SEO, SEM, social

Narender

Narender in Roots Analysis

Presently, more than 120 companies claim to offer AR / VR and affiliated digital marketing services

Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes. These technologies have been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors. Given the increasing demand for immersive technologies in the healthcare and pharma marketing, several stakeholders are expected to forge alliances with AR / VR service providers

Narender

Narender in Roots Analysis

The AR / VR based digital marketing service providers in healthcare sector market

Roots Analysis has done a detailed study on “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 180+ page report, which features 45+ figures and 70+ tables, please visit this link   Key Market Insights §  Presently, more than 120 companies claim to offer AR / VR and affiliated digital marketing services to the global health

Narender

Narender in Roots Analysis

The opportunity for AR / VR based digital marketing service providers in healthcare sector is projected

Roots Analysis has announced the addition of “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” report to its list of offerings.   Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes. These technologies have been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors. Given th

Narender

Narender in Roots Analysis

The ‘Antibody Drug Conjugates Market (5th Edition), 2019-2030

Key Inclusions §  A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target

Narender

Narender in Roots Analysis

Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.   To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this li

Narender

Narender in Roots Analysis

The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 2030

Key Market Insights §  Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives §  Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers §  The pipeline features product candidates that target a wide range of biological antigens

Narender

Narender in Roots Analysis

The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030

Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community   Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.”   The report features an extensive study of the current market landscape, offering an informed op

Narender

Narender in Roots Analysis

×
  • Create New...